ViraBiotech has been established to commercialise an exciting new universal
anti-viral flu treatment that benefits from additional vaccine properties.

ViraBiotech was established in 2006, to commercialise defective interfering virus technology developed by Professor Nigel Dimmock from the University of Warwick.

This is a ground breaking approach to the treatment of influenza.  Its first product FluPro a novel biologic prophylactic combining the benefits of both vaccines and antivirals. It is universal and has a broad window of activity which should also allow it to be a treatment for future pandemic outbreaks. Its mechanism of action is unique and will complement existing drugs for the treatment of flu. Based on current knowledge it will need to be taken a number of times during the season.  However it will be active against all sub-types of influenza and is effective immediately.  It will be delivered intranasally, and hence can be self-administered.

The company and technology platform are based on 40 years of research by Professor Dimmock a world class virologist. A patent has been filed and the company is supported with seed-corn investment from Aitua and Spinner Matched Investment Funds (SMIF) in August 2007. This money has been used to undertake key experiments, attract a high quality management team, consult with large Pharma, apply for public sector funding and develop a robust plan describing activities and milestones for the next 3-5 years.  ViraBiotech is now seeking investment of £750,000 - £1million to take its first product, FluPro through to safety trials in humans